Navigation Links
Mesothelioma drug slows disease progression in patients with an inactive NF2 gene
Date:11/8/2012

Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2. The study is presented at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Friday) [2].

Mesothelioma, which is usually caused by exposure to asbestos, has few treatment options and patients usually die within 9-17 months of diagnosis. Previous research has shown that the gene NF2, which produces a protein called merlin, is frequently inactivated in approximately 50% of mesotheliomas. Merlin negatively regulates another protein called focal adhesion kinase (FAK) in mesothelioma, and so when NF2 and merlin are inactivated, the activity of FAK is increased and mesothelioma cells become invasive and start to spread. When NF2 and merlin activity is restored, FAK activity and cell invasion are decreased.

Professor Jean-Charles Soria, Professor of Medicine and Medical Oncology at South Paris University and head of early drug development at the Institut Gustave Roussy in Paris (France), said: "This suggested that if we could inhibit FAK in mesothelioma patients, it might slow or stop the spread of the disease. Pre-clinical work has shown that an agent, currently known as GSK2256098, is a potent and specific inhibitor of FAK. Early in the clinical study presented today, a patient with mesothelioma, who had progressed quickly on prior therapies, had prolonged stable disease while on GSK2256098, which is suggestive of clinical activity."

Prof Soria and colleagues at nine centres in France, Australia and the United Kingdom recruited 29 mesothelioma patients to the phase I study of GSK2256098, starting in July 2010. The study is continuing.

The mesothelioma patients took the drug orally in capsule form twice a day at doses ranging from 300 - 1500 mg, with the majority (22) taking 1000 mg a day. There were no complete or partial responses; 14 patients had stable disease, nine had progressive disease, three had non-measurable disease, and three left the study before evaluation of response. Overall, patients had an average of 17 weeks before the disease progressed.

However, in patients in whom merlin was inactivated, the average time before the disease progressed was 24 weeks, compared to 11 weeks in patients with active merlin and nearly 11 weeks in patients in whom the activity of merlin was unknown.

Adverse side-effects were mainly low grade and tolerable.

"These findings are important but preliminary," said Prof Soria. "They show that merlin is a potential biomarker in mesothelioma that may enable us to identify a subset of patients who could benefit from GSK2256098 and have longer, progression-free survival. Mesothelioma is a deadly disease without many treatment options, and therefore identification of novel and effective therapies is needed."

The researchers will accumulate and analyse further data, and larger clinical trials will be needed to confirm these findings. In addition, other cancers such as melanoma and meningioma (tumours of the membranes around the central nervous system) show loss of NF2 and merlin function, and so researchers are also investigating whether the findings from this trial may be relevant to other cancers.

Professor Stefan Sleijfer, the scientific chair of the EORTC-NCI-AACR Symposium, from Erasmus University Medical Centre (The Netherlands), commented: "This study strongly suggests that inactivation of merlin may act as a marker to identify patients who may benefit from this compound. Furthermore, better insight into the role of merlin in mesothelioma may lead to novel targets of treatment. This is highly needed given the detrimental prognosis of patients suffering from mesothelioma."


'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
2. Mesothelioma Victims Center Now Urges US Navy Veterans Or Individuals With Mesothelioma To Call Them For The Names Of The Best Mesothelioma Attorneys & Treatment Options
3. The Mesothelioma Victims Center Now Offers The Names Of the Best Mesothelioma Attorneys To Senior Citizens Diagnosed With Mesothelioma Because They Have Rights Too
4. Mesothelioma Victims Center Urges US Navy Veterans or Anyone with Mesothelioma to Call Them for the Names of the Best Mesothelioma Attorneys in the US-Quality Matters
5. Mesothelioma Victims Center Now Offers Its Services to Chemical Plant or Power Plant Workers Living with Mesothelioma Including Naming the Best Mesothelioma Attorneys
6. Mesothelioma Victims Center Now Offers All Families Dealing With A Mesothelioma Diagnosis The Names Of The Best Mesothelioma Attorneys-No Other Group Offers this Service
7. Mesothelioma Victims Center Now Offers A US Navy Veteran Individual Or Family Dealing With Mesothelioma The Names Of The Best Mesothelioma Attorneys--Quality Matters
8. The Mesothelioma Victims Center's Unsurpassed Mesothelioma Victim's Initiative Now Includes Naming The Best Mesothelioma Attorneys Or Mesothelioma Law Firms In The US
9. Mild HIV type slows development of AIDS and makes new preventive treatments possible
10. Infection With 2 HIV Strains Slows Disease Progression
11. Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... , ... June 27, 2017 , ... Today, June 27th ... from PTSD. Yet less than 20% will receive adequate care due to lack of ... won't receive any care at all. And left untreated, veterans are at an increased ...
(Date:6/26/2017)... ... 2017 , ... Antoine Dental Center is now offering various types of dental implants ... as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is ... sturdy, lasting new root for the tooth. , Several types of dental implants are ...
(Date:6/26/2017)... , ... June 26, 2017 , ... LARKR™ , ... health professionals in every state across the country to join its online treatment platform. ... way for therapists to reach a substantially greater number of people in need nationwide, ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... ... Health Month and the focus is on prostate cancer. Second only to skin cancer, ... most common cause of cancer related death today; lung cancer remains in the number one ... cancer during his lifetime. Those at highest risk are men who have a ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
(Date:5/30/2017)... CHICAGO , May 30, 2017 Hill-Rom Holdings, ... th Annual Global Healthcare Conference on Tuesday, June 13, ... John Greisch , Hill-Rom,s president and chief executive officer, ... The live audio webcast can be accessed at ... after conclusion of the live event through September 13, 2017. ...
Breaking Medicine Technology: